The phase II COAST study is particularly interesting as improved clinical efficacy was indicated in patients treated with a combination of CD73 and PD-L1 inhibition compared to PD-L1 inhibition alone for unresectable stage III NSCLC after cCRT. This evidence concerns the gene CD274 and non-small cell lung carcinoma.